Scan to Download ios&Android APP

Trade Guardant Health, Inc. - GH CFD

53.11
3.37%
0.40
Low: 51.23
High: 53.81
Market Trading Hours* (UTC) Opens on Wednesday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading Conditions
Long position overnight fee -0.0225%
Short position overnight fee -0.0219%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 54.96
Open* 53.81
Day's Range* 51.23 - 51.23
1-Year Change* -46.86%
Volume N/A
Average Vol. (3m) 25.283
52 wk Range N/A
Market Cap 5626.21
P/E Ratio N/A
Shares Outstanding 102220000
Revenue 408.13
EPS -5.41225
Dividend (Yield %) N/A
Beta 0.80975
Next Earnings Date Nov 2, 2022

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Aug 16, 2022 53.11 -1.34 -2.46% 54.45 54.45 51.16
Aug 15, 2022 54.96 1.01 1.87% 53.95 56.61 53.69
Aug 12, 2022 54.10 0.83 1.56% 53.27 54.83 52.69
Aug 11, 2022 53.04 -0.18 -0.34% 53.22 56.32 52.36
Aug 10, 2022 52.99 2.44 4.83% 50.55 53.10 49.41
Aug 9, 2022 48.87 -4.69 -8.76% 53.56 53.56 48.47
Aug 8, 2022 54.42 0.89 1.66% 53.53 57.16 53.53
Aug 5, 2022 52.84 5.88 12.52% 46.96 52.84 45.51
Aug 4, 2022 50.91 -0.37 -0.72% 51.28 53.39 50.89
Aug 3, 2022 51.81 0.41 0.80% 51.40 52.29 50.80
Aug 2, 2022 50.60 3.15 6.64% 47.45 51.53 47.24
Aug 1, 2022 48.27 -1.03 -2.09% 49.30 50.33 47.44
Jul 29, 2022 50.11 -1.37 -2.66% 51.48 51.89 49.79
Jul 28, 2022 51.49 1.54 3.08% 49.95 52.79 49.40
Jul 27, 2022 49.91 0.92 1.88% 48.99 50.54 47.43
Jul 26, 2022 48.15 0.20 0.42% 47.95 48.97 47.47
Jul 25, 2022 49.42 1.12 2.32% 48.30 49.58 47.09
Jul 22, 2022 48.38 -2.17 -4.29% 50.55 50.73 47.29
Jul 21, 2022 50.65 2.14 4.41% 48.51 51.01 48.23
Jul 20, 2022 48.41 1.03 2.17% 47.38 49.82 46.36

Guardant Health, Inc. Events

Time (UTC) Country Event
Wednesday, November 2, 2022
10:59
  US
Q3 2022 Guardant Health Inc Earnings Release
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 25.249 49.842 90.639 214.375 286.73 373.653
Revenue 25.249 49.842 90.639 214.375 286.73 373.653
Cost of Revenue, Total 22.124 31.618 43.21 70.72 92.535 122.212
Gross Profit 3.125 18.224 47.429 143.655 194.195 251.441
Total Operating Expense 69.096 131.529 179.331 296.746 541.68 759.654
Selling/General/Admin. Expenses, Total 36.113 69.274 89.657 139.734 299.283 398.521
Research & Development 10.859 25.562 50.714 86.292 149.862 263.221
Unusual Expense (Income) 0 5.075 -4.25 0 0 -25
Operating Income -43.847 -81.687 -88.692 -82.371 -254.95 -386.001
Interest Income (Expense), Net Non-Operating -2.285 -1.468 4.415 12.56 4.905 1.353
Other, Net -0.001 -0.059 0.052 0.088 4.141 0.178
Net Income Before Taxes -46.133 -83.214 -84.225 -69.723 -245.904 -384.47
Net Income After Taxes -46.139 -83.221 -84.263 -67.851 -246.283 -384.77
Net Income Before Extra. Items -46.139 -83.221 -85.063 -75.651 -253.783 -405.67
Net Income -46.139 -83.221 -85.063 -75.651 -253.783 -405.67
Total Adjustments to Net Income 0 -5.774 0 0
Income Available to Common Excl. Extra. Items -46.139 -88.995 -85.063 -75.651 -253.783 -405.67
Income Available to Common Incl. Extra. Items -46.139 -88.995 -85.063 -75.651 -253.783 -405.67
Diluted Net Income -46.139 -88.995 -85.063 -75.651 -253.783 -405.67
Diluted Weighted Average Shares 83.5573 83.5573 85.8325 90.597 97.504 101.314
Diluted EPS Excluding Extraordinary Items -0.55218 -1.06508 -0.99104 -0.83503 -2.6028 -4.00409
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -0.55218 -1.0256 -1.02322 -0.83503 -2.53809 -4.16448
Total Extraordinary Items 0 0 0 0
Minority Interest -0.8 -7.8 -7.5 -20.9
Other Operating Expenses, Total 0.7
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total revenue 78.665 92.101 94.779 108.108 96.099
Revenue 78.665 92.101 94.779 108.108 96.099
Cost of Revenue, Total 28.747 29.927 30.816 33.422 31.981
Gross Profit 49.918 62.174 63.963 74.686 64.118
Total Operating Expense 186.528 189.743 202.067 181.316 219.437
Selling/General/Admin. Expenses, Total 102.273 96.092 100.283 99.873 105.699
Research & Development 55.508 63.724 70.968 73.021 81.757
Operating Income -107.863 -97.642 -107.288 -73.208 -123.338
Interest Income (Expense), Net Non-Operating 0.605 0.293 -0.055 0.01 0.134
Other, Net 0.01 -0.143 -0.087 0.898 -0.048
Net Income Before Taxes -107.248 -97.492 -107.43 -72.3 -123.252
Net Income After Taxes -107.358 -97.575 -107.526 -72.311 -123.228
Minority Interest -2.3 0 0 -18.6 0
Net Income Before Extra. Items -109.658 -97.575 -107.526 -90.911 -123.228
Net Income -109.658 -97.575 -107.526 -90.911 -123.228
Income Available to Common Excl. Extra. Items -109.658 -97.575 -107.526 -90.911 -123.228
Income Available to Common Incl. Extra. Items -109.658 -97.575 -107.526 -90.911 -123.228
Diluted Net Income -109.658 -97.575 -107.526 -90.911 -123.228
Diluted Weighted Average Shares 100.955 101.172 101.42 101.704 101.853
Diluted EPS Excluding Extraordinary Items -1.08621 -0.96445 -1.06021 -0.89388 -1.20986
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -1.08621 -0.96445 -1.06021 -1.05366 -1.20986
Unusual Expense (Income) -25
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 103.091 242.935 468.991 597.358 1888.36 1114.13
Cash and Short Term Investments 95.256 221.32 418.961 522.802 1794.88 932.748
Cash & Equivalents 33.591 72.28 140.544 143.228 832.977 492.202
Short Term Investments 61.665 149.04 278.417 379.574 961.903 440.546
Total Receivables, Net 3.495 12.787 35.69 47.986 53.299 97.652
Accounts Receivable - Trade, Net 3.495 12.787 35.69 47.986 53.299 97.652
Total Inventory 2.769 7.287 9.136 15.181 22.716 30.674
Prepaid Expenses 1.571 1.225 5.204 11.389 17.466 53.052
Total Assets 116.565 342.938 587.403 962.535 2271.78 2204.5
Property/Plant/Equipment, Total - Net 12.634 16.036 31.003 72.808 100.125 313.904
Property/Plant/Equipment, Total - Gross 19.12 26.732 47.637 94.731 134.47 368.728
Accumulated Depreciation, Total -6.486 -10.696 -16.634 -21.923 -34.345 -54.824
Long Term Investments 0 73.254 77.563 268.783 246.597 698.034
Other Long Term Assets, Total 0.84 10.713 9.846 11.772 17.253 60.938
Total Current Liabilities 14.278 19.627 46.944 72.734 66.809 194.687
Accounts Payable 3.157 4.998 10.642 16.197 7.34 17.58
Accrued Expenses 4.012 10.412 18.597 41.21 46.285 83.558
Notes Payable/Short Term Debt 0 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.131 0.199 0.097
Other Current Liabilities, Total 6.978 4.018 17.608 15.327 13.184 93.549
Total Liabilities 36.869 34.332 104.251 164.142 973.286 1559.49
Total Long Term Debt 16.908 0.46 0.119 0 806.292 1134.82
Long Term Debt 16.482 0 806.292 1134.82
Capital Lease Obligations 0.426 0.46 0.119
Other Liabilities, Total 5.683 14.245 15.388 41.808 43.085 229.986
Total Equity 79.696 308.606 483.152 798.393 1298.49 645.005
Preferred Stock - Non Redeemable, Net 179.997 499.974 0
Common Stock 0 0 0.001 0.001 0.001 0.001
Additional Paid-In Capital 7.41 4.9 764.033 1150.09 1902.39 1657.59
Retained Earnings (Accumulated Deficit) -107.625 -195.736 -280.799 -352.809 -606.592 -1007.83
Unrealized Gain (Loss) -0.086 -0.532 -0.083 1.111 2.697 -4.764
Total Liabilities & Shareholders’ Equity 116.565 342.938 587.403 962.535 2271.78 2204.5
Total Common Shares Outstanding 83.5573 83.5573 85.8325 94.2614 100.214 100.214
Other Current Assets, Total 0.316 0
Minority Interest 41.8 49.6 57.1 0
Goodwill, Net 3.29 3.29 3.29
Intangibles, Net 8.524 16.155 14.207
Redeemable Preferred Stock 0 0
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 2033.04 1891.06 1593.41 1114.13 1113.28
Cash and Short Term Investments 1940.45 1791.66 1485.97 932.748 962.266
Cash & Equivalents 869.372 938.59 832.37 492.202 573.604
Short Term Investments 1071.08 853.072 653.601 440.546 388.662
Total Receivables, Net 48.039 53.667 60.744 97.652 84.331
Accounts Receivable - Trade, Net 48.039 53.667 60.744 97.652 84.331
Total Inventory 28.876 26.494 24.739 30.674 36.613
Prepaid Expenses 15.679 19.236 21.958 53.052 30.07
Total Assets 2346.74 2291.89 2225.53 2204.5 2129.6
Property/Plant/Equipment, Total - Net 277.436 290.695 302.592 313.904 339.929
Property/Plant/Equipment, Total - Gross 316.255 334.966 351.876 368.728 401.411
Accumulated Depreciation, Total -38.819 -44.271 -49.284 -54.824 -61.482
Goodwill, Net 3.29 3.29 3.29 3.29 3.29
Intangibles, Net 15.674 15.189 14.698 14.207 13.727
Long Term Investments 0 55.368 250.226 698.034 588.453
Other Long Term Assets, Total 17.297 36.284 61.316 60.938 70.919
Total Current Liabilities 95.501 96.612 102.304 194.687 228.809
Accounts Payable 22.318 21.399 15.674 17.58 32.23
Accrued Expenses 59.7 62.233 75.236 83.558 103.608
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 13.483 12.98 11.394 93.549 92.971
Total Liabilities 1499.69 1503.82 1516.11 1559.49 1596.56
Total Long Term Debt 1132.9 1133.54 1134.18 1134.82 1135.46
Long Term Debt 1132.9 1133.54 1134.18 1134.82 1135.46
Minority Interest 59.4 59.4 59.4 0
Other Liabilities, Total 211.895 214.269 220.23 229.986 232.286
Total Equity 847.046 788.065 709.42 645.005 533.04
Common Stock 0.001 0.001 0 0.001 0
Additional Paid-In Capital 1557.95 1597.42 1626.93 1657.59 1682.41
Retained Earnings (Accumulated Deficit) -711.813 -809.388 -916.914 -1007.83 -1131.05
Unrealized Gain (Loss) 0.904 0.033 -0.593 -4.764 -18.314
Total Liabilities & Shareholders’ Equity 2346.74 2291.89 2225.53 2204.5 2129.6
Total Common Shares Outstanding 101.086 101.265 101.623 100.214 101.896
Other Equity, Total 0.001 0.001
Redeemable Preferred Stock 0 0
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line -46.139 -83.221 -84.263 -67.851 -246.283 -384.77
Cash From Operating Activities -36.71 -72.235 -72.185 -47.134 -103.927 -209.017
Cash From Operating Activities 3.693 5.206 7.136 11.411 16.065 22.271
Non-Cash Items 3.282 10.769 6.069 15.398 173.956 193.95
Cash Taxes Paid 0.014 0.026 0.102 0.298 0.331 0.393
Cash Interest Paid 2.243 1.339 1.251 1.181 0 0
Changes in Working Capital 2.454 -4.989 -1.127 -6.092 -47.665 -40.468
Cash From Investing Activities 26.202 -170.416 -153.028 -317.57 -617.086 -63.155
Capital Expenditures -1.766 -6.681 -20.203 -21.217 -54.059 -75.035
Other Investing Cash Flow Items, Total 27.968 -163.735 -132.825 -296.353 -563.027 11.88
Cash From Financing Activities 39.84 281.656 293.161 367.304 1410.31 -66.824
Issuance (Retirement) of Stock, Net 40.215 307.744 256.99 368.466 372.353 17.865
Issuance (Retirement) of Debt, Net -0.375 -26.088 -0.443 -0.128 1132.58 -0.93
Net Change in Cash 29.332 39.005 67.948 2.684 689.749 -340.689
Financing Cash Flow Items 36.614 -1.034 -94.622 -83.759
Foreign Exchange Effects 0.084 0.455 -1.693
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -107.358 -204.933 -312.459 -384.77 -123.228
Cash From Operating Activities -16.291 -78.884 -132.029 -209.017 -28.619
Cash From Operating Activities 5.01 10.637 16.181 22.271 7.201
Non-Cash Items 62.901 109.108 155.695 193.95 37.25
Changes in Working Capital 23.156 6.304 8.554 -40.468 50.158
Cash From Investing Activities 123.87 250.936 203.542 -63.155 110.808
Capital Expenditures -9.586 -28.261 -50.41 -75.035 -22.7
Other Investing Cash Flow Items, Total 133.456 279.197 253.952 11.88 133.508
Cash From Financing Activities -69.953 -65.044 -70.604 -66.824 -0.012
Financing Cash Flow Items -73.576 -74.958 -82.157 -83.759 -0.957
Issuance (Retirement) of Stock, Net 4.462 10.789 12.466 17.865 0.963
Issuance (Retirement) of Debt, Net -0.839 -0.875 -0.913 -0.93 -0.018
Foreign Exchange Effects -1.087 -1.08 -1.193 -1.693 -0.792
Net Change in Cash 36.539 105.928 -0.284 -340.689 81.385
Cash Taxes Paid 0.393
Cash Interest Paid 0

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
427000+

Traders

71000+

Active clients monthly

$46000000+

Monthly investing volume

$17000000+

Withdrawn each month

Guardant Health Company profile

About Guardant Health Inc

Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer through use of its blood-based tests, data sets and advanced analytics. It has developed its Guardant360, Guardant360 CDx and GuardantOMNI liquid biopsy-based tests for advanced stage cancer. It also developed its Guardant Reveal liquid biopsy-based test for residual and recurring cancer to address the need in Stage II-III colorectal cancer. Its Guardant360 test is a molecular diagnostic test measuring 74 cancer-related genes. Its Guardant360 CDx test is a liquid biopsy test measuring 55 cancer related genes. Its GuardantOMNI test has a broader 500-gene panel, all of which analyze circulating tumor Deoxyribonucleic Acid (DNA) in blood. The Company's tests are used by biopharmaceutical companies for a range of applications, including identifying target patient populations to accelerate translational science research and clinical trial enrollment, and companion diagnostic development.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Guardant Health Inc revenues increased 30% to $373.7M. Net loss increased 60% to $405.7M. Revenues reflect United States segment increase of 33% to $352.6M. Higher net loss reflects Research and development expense increase of 75% to $244.3M (expense), Sales and marketing expense increase of 81% to $176.4M (expense).

Industry: Bio Diagnostics & Testing

3100 Hanover Street
PALO ALTO
CALIFORNIA 94304
US

Income statement

People Also Watch

Ripple to US Dollar

0.38 Price
+2.380% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 21:00 (UTC)
Spread 0.00660

Still looking for a broker you can trust?

Join the 427.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading